Pfizer Inc. (NYSE:PFE) Shares Bought by Gilliland Jeter Wealth Management LLC

by · The Markets Daily

Gilliland Jeter Wealth Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,430 shares of the biopharmaceutical company’s stock after purchasing an additional 2,579 shares during the period. Gilliland Jeter Wealth Management LLC’s holdings in Pfizer were worth $707,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in PFE. Olistico Wealth LLC purchased a new stake in Pfizer during the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $29,000. Quarry LP purchased a new stake in shares of Pfizer during the second quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the period. Finally, Financial Connections Group Inc. purchased a new position in Pfizer in the 2nd quarter valued at $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on PFE shares. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.91.

Read Our Latest Research Report on Pfizer

Pfizer Stock Down 0.2 %

PFE opened at $29.22 on Monday. The stock has a market capitalization of $165.58 billion, a price-to-earnings ratio of -487.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The business has a 50-day moving average of $29.07 and a two-hundred day moving average of $28.45.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.75%. Pfizer’s payout ratio is currently -2,800.00%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).